Signos CEO Sharam Fouladgar-Mercer talks first FDA-approved glucose monitor for weight loss

Product & Technology - Signos leverages AI and continuous glucose monitoring (CGM) via a wearable biosensor to provide real-time metabolic insights for weight management [2][3] - The device, featuring a micro-needle, is worn for 15 days and provides data accessible via a phone app [3][4] - Signos aims to predict weight-related outcomes by providing personalized recommendations (e.g, suggesting a walk after a meal) based on glucose levels [5] - Signos integrates with other wearable devices like Apple Watch, complementing their data with AI-driven predictions [13][14] Market & Competition - Signos positions itself as a complementary solution to GLP-1 drugs, targeting a broader audience beyond those with obesity, focusing on weight loss and maintenance [7] - The company aims to establish metabolism as the "fifth vital sign," promoting continuous monitoring outside of clinical settings [8] - The FDA clearance covers the device's accuracy in measuring glucose levels for weight management, including weight loss and maintenance [9] Business Model & Financials - The service costs $129 per month and is FSA/HSA eligible [6] - Signos is actively pursuing partnerships with insurers for reimbursement coverage [6] Clinical Benefits - Stabilizing glucose levels can lead to improved sleep quality, as demonstrated by a user experience of tripled deep sleep duration [11][12]